54% of Europeans Consider Their Current Physical Health to Be Good or Very Good, as Survey Reveals Public Perceptions of Health Following Nearly Two Years of the COVID-19 Pandemic
25.11.2021 11:00:00 EET | Business Wire | Press release
After two years of the Covid-19 pandemic, results from a European survey reveal that more than half of Europeans rate their physical health as good or very good - with a quarter of respondents reducing their alcohol and drug consumption and one in five saying they eat a healthier diet. Although 45% of Europeans rate their mental health as good or very good, 23% of the youngest (18-29 years old) say they have needed psychological help during the pandemic.
These are just some of the major findings from the "Merck Survey: Europeans' perception of health two years after the start of Covid 19" ; a survey of 6,000 people aged 18 to 65 from ten countries (Germany, Belgium, Spain, France, Italy, Poland, Portugal, United Kingdom, Czech Republic and Switzerland) that the science and technology company Merck carried out with the technical support of GAD3.
"This pandemic has triggered the biggest health, social and economic crisis in almost a century and - from the perspective of having overcome the most critical months of it - in Merck we wanted to know its impact on the health and lifestyle of Europeans,” says Marieta Jiménez, Senior Vice President of Merck Healthcare in Europe. " We believe that only by getting closer and asking people what they feel, think and need can we provide answers to the different health challenges. A healthy society is the basis for building a stronger, safer and more prosperous society," she adds.
The survey shows that Europeans (especially Italians, Spaniards and Portuguese) consider that the pandemic has helped them to talk openly in their personal and professional environment about their physical and mental health. In addition, one in three Europeans say that it has improved family coexistence and feelings of solidarity (34% and 33% respectively). Family co-existence was reported as a particular benefit by more Spaniards ad Czechs than in any other European country surveyed (42% and 45% respectively).
In contrast, the survey emphasizes the weight of emotional problems arising from the pandemic. The results show that 26% of all Europeans have developed a fear of physical contact with other people and 23% of young people surveyed have needed psychological help. Stress and anxiety, followed by fear and uncertainty, are the feelings that have affected more than a third of Europeans (38% and 33%, respectively).
When compared to the European average, stress and anxiety have affected countries such as Spain, Poland and Portugal more, while fear and uncertainty have particularly affected Spain, Italy and Portugal. Germany, Spain, the UK and Poland are the countries most affected by loneliness.
New times, new habits
The pandemic has also boosted the use of new health technologies. The Merck survey concludes that seven out of ten Europeans say they are comfortable or increasingly comfortable with telemedicine. Although most Europeans continue to prefer face-to-face consultations after the health crisis, people from Portugal, France and Italy reported a current preference for telemedicine vs. face-to-face consultations.
The survey further reveals that almost a quarter (24%) of Europeans say they have reduced their alcohol and drug consumption and one in five say they now eat a healthier diet.
Furthermore, only one in ten Europeans have postponed their plans to build or grow a family after the pandemic. People from the Czech Republic and Italy have postponed their intention to have children the most after the pandemic (14% and 15% respectively).
High recognition for health professionals
The study also probes opinions about the work of different health and science professionals during the pandemic. All countries recognize the good work of health personnel. In fact, 70% of Europeans rate the work of health workers and researchers as good or very good. Even so, it is worth noting that the performance of pharmacists during the pandemic was the most highly rated in all countries (compared to doctors, nurses, scientists and researchers) and they were the most highly rated in countries such as Spain and the Czech Republic.
When asked about what should be improved in the health system, 6 out of 10 European countries surveyed agree on the need to invest more in preventive medicine and public health, followed by primary care and mental health. Germans prefer researching new medicines over all other areas, while the British attach greater importance to mental health and the Poles call for greater primary care along with the Spanish.
Which diseases do Europeans fear the most?
In addition, the “ Merck Survey: Europeans' perception of health two years after the start of Covid 19” also points out that 75% of Europeans think that the health crisis has affected the normal course of cancer treatments. Cancer is the most feared disease in the wake of the pandemic, followed by neurodegenerative diseases, such as Alzheimer's or Parkinson's, and cardiovascular diseases.
“We are living unprecedented times and as a curious company we need to prioritize more than ever the value of science and professionals working in the service of health," emphasizes François Feig, Senior Vice President Mid Europe Healthcare at Merck. “This ambitious survey sheds light on the feelings of Europeans about their health after two years of living with Covid and I believe that this information will allow all of us who put our efforts in the service of people's health and well-being to better understand their needs . ”
To access the Merck Survey, please follow this link.
About Merck
Merck, a leading science and technology company, operates across healthcare, life science and electronics. Around 58,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2020, Merck generated sales of € 17.5 billion in 66 countries.
Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Electronics.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211125005676/en/
Contact information
Merck Healthcare Communication:
Belgium - geoffrey.vokes@merckgroup.com Mobile: +31 (0)6 51 42 10 99
Czech Republic - orla.delaney@merckgroup.com Mobile: +41 79 509 07 93
France - constance.de-quinsonas@merckgroup.com Mobile: + 33 (0)6 40 87 79 54
Germany - shenja.schaefer@merckgroup.com Mobile: +49 (0)6151 6285 821
Italy - luca.naponiello@merckgroup.com Mobile: +39 3357386010
Poland - Magdalena.Nelec@merckgroup.com Mobile: +48 692 485 892
Portugal - rita.reis@merckgroup.com Mobile: + 351 931 122 552
Spain - maria-dolores.canton-fernandez@merckgroup.com Mobile: +34 669 296 282
United Kingdom - charlotte.davies@merckgroup.com Mobile: + 44 (0)7779 568540
Switzerland - orla.delaney@merckgroup.com Mobile: +41 79 509 07 93
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
